PTX-COVID19-B: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 29: | Line 29: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 18:41, 18 March 2025
PTX-COVID19-B is a mRNA vaccine candidate developed by Providence Therapeutics and its partner company, Northern RNA, for the prevention of COVID-19. The vaccine is currently in the clinical trial phase.
Etymology[edit]
The name "PTX-COVID19-B" is derived from the initials of the company that developed it, Providence Therapeutics (PT), and the disease it is designed to prevent, COVID-19. The "B" in the name signifies that it is a variant of the original vaccine.
Development[edit]
Providence Therapeutics and Northern RNA began the development of PTX-COVID19-B in early 2020, shortly after the SARS-CoV-2 virus was identified. The vaccine is based on mRNA technology, similar to the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine.
Clinical Trials[edit]
The Phase 1 clinical trial for PTX-COVID19-B began in January 2021, with 60 participants aged 18-64. The trial aims to evaluate the safety, tolerability, and immunogenicity of the vaccine. The results of the Phase 1 trial are expected to inform the design of subsequent Phase 2 and 3 trials.
Mechanism[edit]
PTX-COVID19-B is an mRNA vaccine, which works by introducing a small piece of the SARS-CoV-2 virus's mRNA into the body. This mRNA instructs cells to produce a harmless piece of the virus, triggering an immune response.
